BRKR Stock Overview
Develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Narratives bring a range of perspectives from our community.
Tactical Acquisitions And Innovation Drive Market Expansion And Revenue Growth
Bruker Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$63.37 |
| 52 Week High | US$94.86 |
| 52 Week Low | US$53.79 |
| Beta | 1.18 |
| 11 Month Change | 2.21% |
| 3 Month Change | -4.29% |
| 1 Year Change | 2.61% |
| 33 Year Change | -26.22% |
| 5 Year Change | 47.75% |
| Change since IPO | 174.78% |
Recent News & Updates
We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt
Sep 10
Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In
Aug 22Recent updates
We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt
Sep 10Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In
Aug 22Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 22Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price
Jun 09Bruker: A Confusing Acquisition Spree
May 31Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations
May 09Bruker Corporation: An Aggressive Acquisition Strategy
Apr 24Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research
Apr 11Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)
Jan 22There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price
Jan 08Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?
Dec 26Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?
Nov 06Is Bruker (NASDAQ:BRKR) Using Too Much Debt?
Oct 23Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors
Sep 25Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?
Aug 09Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?
Jul 27Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet
Jul 11If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity
Jun 26Shareholder Returns
| BRKR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -3.6% | -1.3% | -3.4% |
| 1Y | 2.6% | 8.5% | 19.6% |
Return vs Industry: BRKR underperformed the US Life Sciences industry which returned 8.5% over the past year.
Return vs Market: BRKR underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 4.7% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BRKR has not had significant price volatility in the past 3 months.
Volatility Over Time: BRKR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 9,707 | Frank Laukien | www.bruker.com |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
Bruker Corporation Fundamentals Summary
| BRKR fundamental statistics | |
|---|---|
| Market cap | US$9.59b |
| Earnings (TTM) | US$352.10m |
| Revenue (TTM) | US$3.12b |
27.2x
P/E Ratio3.1x
P/S RatioIs BRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRKR income statement (TTM) | |
|---|---|
| Revenue | US$3.12b |
| Cost of Revenue | US$1.54b |
| Gross Profit | US$1.58b |
| Other Expenses | US$1.22b |
| Earnings | US$352.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.33 |
| Gross Margin | 50.52% |
| Net Profit Margin | 11.29% |
| Debt/Equity Ratio | 116.3% |
How did BRKR perform over the long term?
See historical performance and comparison